Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons
Michael G. Ison, Alberto Papi, Eugene Athan, et al.
Clinical Infectious Diseases (2024) Vol. 78, Iss. 6, pp. 1732-1744
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
Alexander Domnich, Andrea Orsi, Piero Luigi Lai, et al.
Medicina (2025) Vol. 61, Iss. 1, pp. 67-67
Open Access | Times Cited: 1
Would senior citizens get vaccinated against RSV? Exploratory analysis using a novel survey instrument
Mohammad Abu-Ghosh, D. Saleh, Joud Al-Haddad, et al.
Vacunas (2025) Vol. 26, Iss. 1, pp. 100384-100384
Open Access | Times Cited: 1
The recent landscape of RSV vaccine research
Karen Kelleher, N. Subramaniam, Simon B. Drysdale
Therapeutic Advances in Vaccines and Immunotherapy (2025) Vol. 13
Open Access | Times Cited: 1
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States
Daniel Molnar, Elizabeth M. La, Frederik Verelst, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 4, pp. 827-844
Open Access | Times Cited: 12
Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Matteo Riccò, Antonio Cascio, Silvia Corrado, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 500-500
Open Access | Times Cited: 10
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis
Amanda B. Payne, Janet A. Watts, Patrick K. Mitchell, et al.
The Lancet (2024) Vol. 404, Iss. 10462, pp. 1547-1559
Closed Access | Times Cited: 9
Respiratory syncytial virus infections in adults: a narrative review
Joanne Wildenbeest, David M. Lowe, Joseph F. Standing, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 10, pp. 822-836
Closed Access | Times Cited: 8
Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures
Charles Nuttens, Juliette Moyersoen, Daniel Curcio, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 8, pp. 1725-1742
Open Access | Times Cited: 7
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial
Rebecca A. Clark, S. T. Davies, Jorge Labrador, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 4, pp. 1088-1098
Open Access | Times Cited: 7
Adjuvant system AS01: from mode of action to effective vaccines
François Roman, Wivine Burny, Maria Angeles Ceregido, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 715-729
Open Access | Times Cited: 5
Respiratory syncytial virus: challenges in diagnosis and impact on the elderly: Recommendations from a multidisciplinary panel
Lessandra Michelin, Nancy Bellei, Marcelo Ferreira da Costa Gomes, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 5
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
Jonne Terstappen, Sarah F Hak, Anant Bhan, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 12, pp. e747-e761
Closed Access | Times Cited: 5
Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults
Zhanwei Du, Abhishek Pandey, Seyed M. Moghadas, et al.
Nature Medicine (2025)
Open Access
RSVPreF3 OA respiratory syncytial virus vaccine in older adults: a profile of its use
Matt Shirley
Drugs & Therapy Perspectives (2025)
Open Access
Respiratory syncytial virus vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine
Tiago M. Alfaro, Filipe Froes, Cláudia Vicente, et al.
Pulmonology (2025) Vol. 31, Iss. 1
Open Access
The Potential Public Health Impact of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine Among Older Adults in Italy
Anna Puggina, Filippo Rumi, Eleftherios Zarkadoulas, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 212-212
Open Access
Comprehensive management of pneumonia in older patients
Alain Putot, Nicolas Garin, Jordi Rello, et al.
European Journal of Internal Medicine (2025)
Open Access
Perceived benefits, information, vaccination history, and conspiracy beliefs as significant determinants of RSV vaccine acceptance among Arab seniors
Malik Sallam, Kholoud Al-Mahzoum, Zainab Mansour Yousef, et al.
Therapeutic Advances in Vaccines and Immunotherapy (2025) Vol. 13
Open Access
Age-related changes in the immune system and challenges for the development of age-specific vaccines
Mark Doherty, Birgit Weinberger, Arnaud M. Didierlaurent, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access
Whole-Genome Sequencing and Genetic Diversity of Human Respiratory Syncytial Virus in Patients with Influenza-Like Illness in Sicily (Italy) from 2017 to 2023
Fabio Tramuto, Carmelo Massimo Maida, Giulia Randazzo, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 851-851
Open Access | Times Cited: 4
Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus
Shreya Mukhopadhyay, Ioannis Manolaridis, Christopher L. Warren, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 35-35
Open Access
Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines
Cleo Anastassopoulou, Snežana Medić, Stefanos Ferous, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 97-97
Open Access
Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development
Pius I. Babawale, Iván Martínez-Espinoza, Andrew Mitchell, et al.
Pathogens (2025) Vol. 14, Iss. 2, pp. 104-104
Open Access
Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review
Teresa Gavaruzzi, Andrea Ceccarelli, Cristina Nanni, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 159-159
Open Access
Update on vaccines against respiratory syncytial virus (RSV): A narrative review
José Gutierrez-Rodriguez, Jaime Rodríguez-Salazar, Francisco José Tarazona‐Santabalbina
Revista Española de Geriatría y Gerontología (2025) Vol. 60, Iss. 2, pp. 101630-101630
Closed Access
Page 1 - Next Page

Scroll to top